July 14, 2025 09:30 AM EDT
R&D
Pharma

Mer­ck sends new month­ly oral PrEP to Phase 3 af­ter ear­li­er is­la­travir set­back

Kyle LaHucik

Biotech Correspondent

KI­GALI, RWAN­DA — Three years af­ter a safe­ty dis­ap­point­ment halt­ed ear­li­er plans for a once-month­ly HIV PrEP can­di­date, Mer­ck is back in the late stages of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA de­clines to ap­prove Ul­tragenyx's San­fil­ip­po gene ther­a­py, cit­ing man­u­fac­tur­ing is­sues

As­traZeneca posts a piv­otal tri­al win for blood pres­sure pill be­hind $1.3B deal

Take­da’s first-in-class nar­colep­sy drug suc­ceeds in two reg­is­tra­tional stud­ies

Boehringer, LEO ink deal for IL-36 drug; Bay­er’s Keren­dia gets an­oth­er in­di­ca­tion

WHO adds Gilead­'s twice-year­ly in­jec­tion to glob­al PrEP guide­lines

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

A service from the Financial Times